Louisiana State Employees Retirement System Purchases Shares of 46,500 Sarepta Therapeutics, Inc. $SRPT

Louisiana State Employees Retirement System purchased a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 46,500 shares of the biotechnology company’s stock, valued at approximately $1,012,000.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Kestra Advisory Services LLC purchased a new stake in shares of Sarepta Therapeutics during the fourth quarter valued at $25,000. iSAM Funds UK Ltd acquired a new stake in shares of Sarepta Therapeutics during the third quarter worth about $25,000. Ancora Advisors LLC lifted its holdings in shares of Sarepta Therapeutics by 200.0% during the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 1,000 shares during the period. Allworth Financial LP boosted its position in Sarepta Therapeutics by 2,098.8% in the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 1,721 shares during the last quarter. Finally, Parallel Advisors LLC boosted its position in Sarepta Therapeutics by 165.3% in the third quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 1,256 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock opened at $19.28 on Friday. The stock has a market capitalization of $2.04 billion, a PE ratio of -20.08, a price-to-earnings-growth ratio of 0.20 and a beta of 0.21. Sarepta Therapeutics, Inc. has a 12 month low of $10.41 and a 12 month high of $25.32. The business has a 50 day simple moving average of $17.85 and a 200-day simple moving average of $19.34. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.63 and a quick ratio of 2.62.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $2.18. Sarepta Therapeutics had a positive return on equity of 7.56% and a negative net margin of 2.94%.The firm had revenue of $730.80 million for the quarter, compared to analyst estimates of $474.15 million. During the same quarter last year, the firm posted ($3.42) EPS. The business’s revenue was down 1.9% on a year-over-year basis. On average, analysts anticipate that Sarepta Therapeutics, Inc. will post 3.95 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on SRPT shares. Mizuho raised their price target on shares of Sarepta Therapeutics from $26.00 to $31.00 and gave the stock an “outperform” rating in a research report on Thursday, March 12th. Wall Street Zen raised shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday. Wedbush increased their price objective on shares of Sarepta Therapeutics from $29.00 to $35.00 and gave the stock an “outperform” rating in a research note on Thursday, March 26th. Needham & Company LLC reaffirmed an “underperform” rating on shares of Sarepta Therapeutics in a report on Thursday, March 26th. Finally, Weiss Ratings downgraded Sarepta Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, June 29th. Eight investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and six have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $24.81.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.